At Yazen, the medical team follows the principle of the lowest effective dose. This means that medication is never increased automatically simply because a standard dosing schedule recommends it. Together with the treating physician, results, weight loss, and overall well-being are continuously evaluated.

If a patient experiences reduced food noise, good satiety, and steady weight loss at a lower dose, such as 0.5 mg, treatment will generally continue at that level. The goal is to identify the exact amount of medication the body needs to regulate appetite.

Data show that Yazen patients, on average, use 60% lower doses than those used in clinical studies.

It is important to remember that Ozempic is approved for the treatment of type 2 diabetes, while Wegovy contains the same active ingredient (semaglutide) but has been specifically developed and approved for the treatment of obesity and weight loss, partly because it allows for higher doses that have a greater effect on appetite regulation and weight reduction.

Staying on the lowest dose that provides the desired effect offers several important benefits. Medically, it helps protect the body from unnecessary side effects, such as nausea and gastrointestinal discomfort, which may become more common as the dose increases.

In addition to the medical benefits, Yazen's approach may also reduce the overall cost of treatment. The monthly cost of Ozempic largely depends on how quickly the contents of the injection pen are used. By avoiding unnecessary dose increases and identifying the lowest effective maintenance dose, the same pen can last longer.

Ozempic is available as a solution in a pre-filled injection pen in the following dose strengths 0,25 mg, 0,5 mg, 1 mg och 2 mg.